Please login to the form below

Not currently logged in
Email:
Password:

Seroxat

This page shows the latest Seroxat news and features for those working in and with pharma, biotech and healthcare.

UK government fines GSK over 'pay-for-delay' deals

UK government fines GSK over 'pay-for-delay' deals

The CMA's decision relates to activities between 2001 and 2004 in which GSK agreed to pay £50m to companies supplying generic versions of Seroxat (paroxetine) in order to delay their ... Seroxat had been due to be sold off by GSK as part of a plan to

Latest news

  • GSK holds on to older products GSK holds on to older products

    £185m. Other products in GSK's established portfolio with declining sales include antidepressant Seroxat/Paxil (paroxetine) and antiviral drug Valtrex (valacyclovir), both of which had a double digit fall in revenues

  • GSK plans to sell off older products GSK plans to sell off older products

    Imitrex (sumatriptan) for migraine, the antidepressant Paxil/Seroxat (paroxetine) and gastrointestinal therapy Zantac (ranitidine) have all been named in dispatches as former blockbuster brands that are now in GSK's 'established

  • Hisamitsu's Noven unit signs Brisdelle deal with Shionogi Hisamitsu's Noven unit signs Brisdelle deal with Shionogi

    Brisdelle contains 7.5mg of paroxetine, which - at a slightly higher dose - is the active ingredient in antidepressants like GlaxoSmithKline's now off-patent Seroxat/Paxil. ... In common with Seroxat Brisdelle also carries a Boxed Warning about

  • This month in 2000: The formation of GSK This month in 2000: The formation of GSK

    Since then, GSK has been consistently one of the world's best-performing healthcare companies, led by such prescription drugs as asthma treatment Advair/Seretide (fluticasone/salmeterol) and the antidepressant

  • Pay-for-delay deals lead to inflated drug prices says study Pay-for-delay deals lead to inflated drug prices says study

    Of these companies, Lundbeck is facing a penalty of 240m. Meanwhile, the UK Office of Fair Trading has accused GlaxoSmithKline of blocking the entry of generic versions of its Seroxat (paroxetine)

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics